PP-405

Clinical Summary

PP-405 is a first-in-class topical small molecule that inhibits the mitochondrial pyruvate carrier (MPC), developed by Pelage Pharmaceuticals (UCLA spin-out). It reactivates dormant hair follicle stem cells by shifting their metabolism from oxidative phosphorylation to glycolysis — a non-hormonal mechanism mechanistically distinct from finasteride/dutasteride (anti-androgens) and minoxidil (vasodilator).

The compound was discovered by the Michael Jung lab at UCLA (~2013), with the foundational science published in Nature Cell Biology (2017, PMID 28812580, 288+ citations). Pelage was spun out via the Magnify Incubator at UCLA's CNSI and raised $120M Series B in October 2025 (ARCH Venture Partners + Google Ventures).

Phase 2a interim results (July 2025): In 78 men and women with AGA, 31% of men with advanced hair loss (Norwood IV-V) showed >20% increase in hair density at Week 8 vs 0% placebo. The compound induced new terminal hair growth where no hair existed — a regeneration signal not seen with existing treatments. No systemic absorption was detected. No systemic adverse events occurred.

Critical context: PP-405 is NOT JXL-069. Pelage has explicitly stated they are distinct molecules from the same research lineage. Grey-market "PP-405" products are almost certainly JXL-069 or unknown analogues with unverified purity. Multiple scam products exist (Amazon listings, fraudulent websites).

Earliest possible market availability: 2028–2030, assuming Phase 3 starts 2026 and proceeds without delays.

Indications & Evidence

Reading this table: Stars = evidence volume. Type = what kind of evidence (see legend). BH = Bradford Hill causal strength (/9). Safety = FAERS/trial signals for THIS specific indication. One row = one decision.

Hard rule: Star rating cannot exceed the causal taxonomy ceiling for its Type. E.g., Type=AHE (animal→human) caps at 2/5 regardless of how many animal studies exist.

Type codes: DC=Direct causation | PC=Probable | UCC=Unreplicated causal | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal→human | OA=Observational | RC=Reverse causation | CF=Confounded | FA=Folk/anecdotal | NE=No evidence BH: Bradford Hill criteria met (of 9). 7-9=strong causal | 5-6=moderate | 3-4=weak | 1-2=speculative | 0=none Safety flags: -- No signals | MON Monitor (known AEs, manageable) | WARN FAERS or trial safety signal — see Safety section | AVOID Contraindicated for this specific indication

Star rating legend:

Prescribing

Dosing Table

Formulation Table

Note: The vehicle/gel formulation is critical — the clinical formulation ensures scalp penetration. Raw powder in arbitrary solvents (as sold by grey-market vendors) may not penetrate and lacks safety data.

Safety

Interactions Table

Contraindications

• Known hypersensitivity to PP-405 or any gel vehicle component
• Open wounds or active skin infection at application site (standard topical precaution)
• Pregnancy/lactation — no reproductive toxicity data exists; avoid per precautionary principle
• No systemic contraindications identified (no systemic absorption)

Adverse Effects (ranked by frequency)

From Phase 1 (N=20) + Phase 2a (N=78) — total exposure: 98 subjects, max 84 days:

1. Temporary local redness — mild, self-resolving (most common)
2. Mild itching at application site — transient
3. Short-lived local irritation — minimal

No serious adverse events. No systemic adverse events. No discontinuations for adverse events reported.

Evidence quality for safety: 2/5 (very limited). 98 subjects with max 84-day exposure is insufficient to detect rare or long-term adverse effects. "Well tolerated" at this stage = "no red flags yet," not "proven safe."

FAERS Signal Table (from BioMCP)

Monitoring Table

Special Populations

Renal Impairment

Not applicable — no systemic absorption. No dose adjustment needed.

Hepatic Impairment

Not applicable — no systemic absorption. No dose adjustment needed.

Pediatric

No data. Not studied in patients <18.

Synergies & Stacking

All stacking evidence is theoretical. No clinical combination studies exist for PP-405 with any other treatment.

Individual Response Modifiers

Sex-Specific Considerations

Note: If Phase 3 confirms efficacy in women, PP-405 would fill a major unmet need — currently only Minoxidil is approved for female AGA. Finasteride and Dutasteride are contraindicated in women of childbearing potential.

Genetic Modifiers

No known pharmacogenomic modifiers for PP-405. Given topical administration with zero systemic absorption and no hepatic metabolism, traditional CYP/transporter polymorphisms are irrelevant.

Theoretical modifier: Genetic variation in MPC1/MPC2 expression in hair follicle stem cells could influence responder status. Not studied. No SNPs cataloged for this specific drug-gene interaction.

Community & Anecdotal Evidence

Disclaimer: This section captures real-world user reports from online communities. None of this constitutes clinical evidence. N-sizes are approximate. Selection bias, placebo effect, and recall bias are inherent. Presented for completeness, not as medical guidance. CRITICAL: Most community "PP-405 experience" is actually JXL-069 experience — a related but distinct molecule. Pelage has explicitly confirmed PP-405 ≠ JXL-069.

Dominant Sentiment

Cautiously optimistic / speculative across ~200-500 discussion participants (primarily r/Tressless, Tressless.com). Actual self-experimenters who sourced grey-market JXL-069: estimated N ≈ 20-50.

What Users Report

Community Dosing vs Clinical

Popular Stacks (Community)

Red Flags & Skepticism Notes

• MLM involvement: None detected — positive signal
• Influencer concentration: No single-influencer hype pattern. Interest is distributed across the hair loss community
• Astroturfing signals: Hair transplant clinic SEO content is significant — dozens of clinics published "What is PP405?" articles as search-traffic funnels toward existing services (transplants, PRP, minoxidil). Not independent evidence
• Commercial bias: Amazon listings for "PP405 Hair Treatment" serums contain hyaluronic acid + biotin, NOT the actual compound. pp405-shop.com flagged as scam (ScamAdviser score: 22.2/100). pp405.online flagged as high-risk. Multiple Chinese suppliers sell "PP405/JXL-069 raw powder" of unknown purity
• Identity crisis: PP-405 ≠ JXL-069. Grey-market products are almost certainly JXL-069 or unknown analogues. Community advice: demand batch-level COAs (HPLC/UPLC, purity %, ideally NMR/HRMS)

Folk vs Clinical Reality Check

Community experience with grey-market JXL-069 is underwhelming compared to Phase 2a clinical excitement — which is expected. The clinical formulation (proprietary 0.05% gel) was optimized for scalp penetration; raw powder in arbitrary solvents likely doesn't penetrate as effectively. Additionally, JXL-069 is a different molecule than PP-405, so grey-market results may not predict clinical PP-405 performance at all. The absence of any reported systemic effects in community use does align with clinical data showing zero systemic absorption.

Deep Dive: Mechanisms & Research

Mechanism of Action (Detail)

PP-405 inhibits the mitochondrial pyruvate carrier (MPC), a heterodimer of MPC1 and MPC2 that transports pyruvate across the inner mitochondrial membrane for oxidative phosphorylation. Blocking MPC:

1. Pyruvate accumulates in the cytoplasm
2. Lactate dehydrogenase (LDH) converts excess pyruvate to lactate
3. Elevated lactate acts as a metabolic signal that shifts hair follicle stem cells (HFSCs) from quiescence (telogen) to activation (anagen)
4. HFSCs enter the cell cycle, proliferate (Ki67+ confirmed in Phase 1 biopsies), and regenerate hair follicles
5. New terminal hairs emerge — not just vellus-to-terminal conversion, but de novo follicle activation

This metabolic reprogramming toward glycolysis resembles the Warburg effect seen in cancer cells and stem cells. The Warburg-like state is required for stem cell activation across multiple tissue types (hair, neural, intestinal).

Clinical translation status: The mechanism has been validated from mouse models (2017) → preclinical alopecia models (2021) → independent human ex vivo confirmation (Manchester, 2024) → Phase 1 biopsy confirmation (Ki67 activation, 2024) → Phase 2a clinical efficacy (2025). This is a strong translational pathway.

Independent validation (Manchester, 2024): Pye et al. found that MPC inhibition in human hair follicle organ culture activated the integrated stress response (ISR) — suggesting the human follicle response involves pathways beyond the simple lactate/LDH model from mouse studies. This adds mechanistic complexity and potential additional therapeutic angles, but also means the full mechanism in humans is not yet fully characterized.

MPC Inhibitor Class Context

PP-405 is the first topical MPC inhibitor. Related systemic MPC inhibitors provide class safety context:

PP-405 is topical-only with zero systemic absorption, making systemic class concerns largely academic. The Warburg-effect/cancer concern (glycolysis shift = cancer hallmark) is mitigated by: (a) topical-only exposure, (b) the Flores 2019 paper (PMID 30626875) showing increased LDH was dispensable for squamous carcinoma transformation in HFSCs.

Broader MPC Biology (Cross-Tissue)

MPC inhibition activates stem cells beyond hair follicles:

• Neural stem cells: MPC inhibition reactivates quiescent adult neural stem cells (Science Advances 2023, Geneva/Lausanne, 78 citations)
• Cardiac metabolism: MPC modulates cardiac hypertrophy (Nature Metabolism 2020)

These findings suggest MPC is a universal stem cell metabolic switch. However, PP-405's topical formulation and zero systemic absorption mean these cross-tissue effects are irrelevant to its clinical use.

Clinical Trials (from BioMCP / ClinicalTrials.gov)

No trials registered in East Asian registries (JPRN, CRiS, ChiCTR, Taiwan). All clinical development is US-based across 8 sites (CA, IN, MN, TX, UT, VA).

Regulatory Status (from BioMCP)

• FDA: Not approved. IND status presumed (required for US clinical trials)
• EMA: No submissions or approvals
• PMDA (Japan): No submissions
• NMPA (China): No submissions
• Regulatory context: Pre-market investigational drug. Phase 3 planned 2026. Regulatory submissions would follow successful Phase 3 completion, likely 2028+ at earliest. The compound is not "not approved for safety reasons" — it simply hasn't completed clinical development yet.

East Asian Research

No PP-405-specific research from Japanese, Korean, or Chinese institutions. The cyano-cinnamate MPC inhibitor chemistry paper (PMID 39134097, Huang et al. 2024) may have Chinese institutional affiliation — the only tangentially related East Asian contribution.

Ataraxia Verdict (as of 2026-04-14)

Evidence Classification (Mode 5: Evidence Classifier)

Synthesized view in Indications & Evidence table above (Type + BH + Safety columns). Detailed rationale for each classification below.

Bradford Hill scoring rationale (AGA male, advanced):

1. Strength: 31% vs 0% placebo responder rate — strong
2. Consistency: Single trial only — cannot assess
3. Specificity: MPC inhibition → HFSC activation → hair growth is specific
4. Temporality: Treatment preceded response; confirmed in Phase 1 (Ki67 activation at 7 days)
5. Biological gradient: Phase 1 found 1x/day = 2x/day — no clear dose-response
6. Plausibility: Well-characterized mechanism (Nature Cell Biology 2017, independent Manchester 2024 confirmation)
7. Coherence: Manchester ISR finding adds complexity — mechanism may be more nuanced than Pelage's narrative
8. Experiment: Placebo-controlled RCT design; Ki67 biomarker confirmed
9. Analogy: MPC inhibition in neural stem cells provides analogical support but in different tissue

Hype Check (Mode 1: Fallacy Radar)

• Appeal to novelty: "First-in-class" framing creates excitement disproportionate to evidence maturity. First-in-class drugs fail at ~85% rates in Phase 3 (industry average)
• Hasty generalization: 78-patient Phase 2a interim data → "hair loss is solved" narrative in community. Phase 2a is designed to test safety and signal efficacy, not confirm it
• Appeal to authority: Nature Cell Biology 2017 paper cited repeatedly as definitive proof. It's foundational but mouse-to-human is still the biggest risk
• Cherry-picking (potential): Only interim Phase 2a data reported publicly. Full dataset including non-responders, adverse events by severity, and sex-stratified results not yet published. 31% responder rate means 69% did NOT respond
• Survivorship bias (community): Grey-market experimenters who saw no results may have stopped posting. Positive reports are more likely to be shared

Evidence Gaps

• No long-term data: Maximum exposure is 84 days (Phase 2a OLE). Hair growth is a long-term proposition — does effect sustain at 6, 12, 24 months?
• No dose-response curve: Only 0.05% studied clinically. Phase 1 found 1x/day = 2x/day, which is unusual and not fully explained
• No female-specific data: Women enrolled but results not stratified by sex
• No combination therapy data: All theorized stacks (finasteride, minoxidil, microneedling) are untested
• No independent clinical replication: All clinical data is sponsor-generated (Pelage Pharmaceuticals)
• ISR mechanism unclear: Manchester 2024 finding (integrated stress response in human follicles) adds complexity — the clean LDH/lactate narrative may oversimplify
• Responder characterization: Why 31% and not higher? What predicts response? Genetic, hormonal, or follicle-state factors?
• No comparison to existing treatments: No head-to-head data vs finasteride, minoxidil, or combination therapy
• Cancer safety: Warburg effect (glycolysis shift) is a cancer hallmark. While the Flores 2019 paper (PMID 30626875) is reassuring and topical-only application limits exposure, long-term local carcinogenicity in scalp tissue has not been studied

Bias Flags (Mode 4: First Principles)

• All clinical data is sponsor-generated. Pelage Pharmaceuticals funded, designed, and reported all trials. No independent clinical replication exists
• Founder-researcher alignment: The scientists who published the foundational research (Flores, Christofk at UCLA) founded the company. This alignment of incentives is normal in biotech but means commercial success depends on the same people's research holding up
• $120M creates reporting pressure. With ARCH Venture Partners and Google Ventures invested, there is strong pressure to present favorable data. Interim data release ahead of full publication is a common biotech tactic
• No peer-reviewed clinical publications. Phase 1 results were presented at AAD 2024 (conference abstract, not peer-reviewed). Phase 2a results reported via press release. Neither has undergone peer review
• Foundational science IS strong. The 2017 Nature Cell Biology paper (288 citations) and independent Manchester 2024 replication provide genuine mechanistic credibility that is unusual for early-stage hair loss treatments

Manipulation Flags (Mode 2: Manipulation Shield)

• Industry marketing: Pelage's PR is professional but measured — they haven't made exaggerated claims. However, "first-in-class," "regeneration signal," and "new hair where none existed" are carefully chosen language designed to maximize investor and community excitement
• Influencer economics: No significant influencer ecosystem detected. Hair loss community interest is organic, not manufactured. Positive signal
• Counter-narrative manipulation: Hair transplant clinics are publishing SEO content ("What is PP405?") that subtly steers readers toward existing paid services. Not anti-PP405 per se, but commercially motivated
• Cui bono summary: Pelage wins if PP-405 succeeds ($120M invested, $3.6B+ hair loss market). Finasteride/minoxidil manufacturers face marginal competitive threat. Hair transplant industry loses if medical therapy improves sufficiently. The academic researchers (Flores, Christofk) win both scientifically and commercially — unusual dual incentive
• Red team highlight: The single most concerning angle is the 69% non-responder rate. In a community desperate for hair loss solutions, the 31% headline will be remembered while the majority who didn't respond will be forgotten. Phase 3 needs to address this gap clearly

10-angle red team:

1. Logical consistency: Mechanism → data chain is internally consistent ✓
2. Evidence quality: Phase 2a interim is low on the evidence hierarchy ️
3. Cui bono: Strong commercial incentive for positive framing ️
4. Time horizon: 8-week endpoint is very short for hair growth ️
5. Steelman: Genuine novel mechanism with independent validation is rare and valuable ✓
6. Reversibility: Topical with no systemic absorption = highly reversible; low downside ✓
7. Second-order effects: ISR activation in human follicles (Manchester) may have uncharacterized consequences ️
8. Historical precedent: Many "breakthrough" hair loss treatments have failed in Phase 3 ️
9. Emotional loading: Hair loss community is desperate → susceptible to hype ️
10. Stranger test: Would a disinterested observer invest based on N=78, 8-week interim data? Probably not ️

Decision Support (Mode 3: Clarity Compass)

• Health utility score: 3/10 — topical-only investigational hair-loss compound (MPC inhibitor) targeting a single indication (androgenetic alopecia); not commercially available, Phase 3 pending, and grey-market JXL-069 is a separate unverified molecule. High utility ceiling if Phase 3 succeeds, but zero current utility.
• Opportunity cost: Monitoring an investigational compound that isn't available for purchase has zero cost. Self-experimenting with grey-market JXL-069 has significant cost (unverified purity, unknown molecule, no safety monitoring) for likely underwhelming results
• Hell Yes or No: No — cannot use it even if you wanted to. Not commercially available
• Regret minimization: In 5 years, would you regret not tracking this? No — if Phase 3 succeeds, it'll be major news. If it fails, no loss. No action required now
• Verdict: WATCH LIST — revisit when Phase 3 data is published (expected ~2027-2028). Do NOT self-experiment with grey-market JXL-069

Bottom Line

PP-405 is a legitimate early-stage therapeutic with a genuinely novel mechanism (MPC inhibition → HFSC metabolic reprogramming) backed by strong foundational science and independent mechanistic validation. The Phase 2a signal (31% responder rate, regeneration in advanced AGA, zero systemic absorption) is promising but preliminary — 78 subjects, 8-week interim data, sponsor-reported, not peer-reviewed. The 69% non-responder rate is underemphasized. First-in-class drugs fail in Phase 3 at ~85% rates.

For the IdeaVerse reader: This is a WATCH compound. Track Phase 3 enrollment and results. Do not purchase grey-market "PP-405" products — they are not PP-405, they are unverified, and they underperform the clinical formulation. If Phase 3 confirms efficacy and regulatory approval follows, this could be the first genuinely new mechanism for hair loss treatment in decades.

Practical Notes

Brands & Product Selection

PP-405 is not commercially available. All clinical-grade PP-405 is manufactured by or for Pelage Pharmaceuticals for clinical trials only.

WARNING: Products marketed as "PP-405" online are fraudulent:

• Amazon "PP405 Hair Treatment" serums contain hyaluronic acid + biotin — not PP-405
• pp405-shop.com: ScamAdviser score 22.2/100 — likely scam
• pp405.online: flagged as high-risk
• Chinese suppliers selling "PP405/JXL-069 raw powder": unverified purity, may not be either compound
• Umbrella Labs and similar vendors sell JXL-069 (not PP-405) as a research chemical

If self-experimenting with grey-market JXL-069 (not recommended): demand batch-level COAs with HPLC/UPLC purity %, ideally NMR/HRMS identity confirmation.

Storage & Handling

Not applicable — not commercially available. Clinical formulation (0.05% gel) storage conditions not publicly disclosed.

Palatability & Compliance

Topical gel applied once daily to scalp. Phase 1 established that once-daily is equivalent to twice-daily in biological response, simplifying compliance.

Exercise & Circadian Timing

No data. No exercise or time-of-day considerations identified.

Reference Ranges (Expected Biomarker Changes)

Cost

Not applicable — investigational drug. No pricing data.

Projected: If approved, pricing will likely be premium (novel mechanism, first-in-class). Hair loss prescription market reference: finasteride generic ~$10-30/mo, branded minoxidil ~$30-60/mo, compounded combinations $50-200/mo.

What We Don't Know

• Long-term efficacy: Does hair regrowth sustain beyond 8 weeks? Does it plateau? Does it reverse on discontinuation?
• Long-term safety: 84 days is the maximum exposure studied. Chronic topical application (years) has not been evaluated
• Local carcinogenicity: MPC inhibition induces Warburg-like glycolysis in scalp cells. Long-term cancer risk at application site is unknown
• Female efficacy: Women enrolled but sex-stratified results not published
• Responder prediction: No biomarker or clinical feature predicts who will respond (31%) vs not (69%)
• Full Phase 2a dataset: Only interim results via press release. Full data including detailed safety, all endpoints, and subgroup analyses awaits medical meeting presentation and peer-reviewed publication
• Combination therapy: All theorized stacks (with finasteride, minoxidil, microneedling, PRP) are untested
• Hair quality: Is regrown hair terminal (thick, pigmented) or intermediate? Phase 2a claims terminal hair but detailed characterization not published
• ISR implications: Integrated stress response activation (Manchester 2024) in human follicles is not fully characterized — potential beneficial or adverse consequences unknown
• Dose optimization: Only 0.05% studied. Higher or lower concentrations may be more effective
• Alopecia areata / other types: MPC mechanism is not AGA-specific but no non-AGA clinical data exists
• Exact molecular identity of PP-405: Chemical structure not publicly disclosed (proprietary)

References

Foundational / Mechanism Studies

• Flores A, Schell J, Krall AS, et al. Lactate dehydrogenase activity drives hair follicle stem cell activation. Nature Cell Biology. 2017;19(9):1017-1026. PMID: 28812580 — Foundational paper establishing MPC/LDH/lactate mechanism for HFSC activation. 288+ citations.
• Flores A, Choi S, Hsu YC, et al. Inhibition of pyruvate oxidation as versatile stimulator of hair cycle in alopecia models. Exp Dermatol. 2021;30(4). PMID: 33739490 — Preclinical validation in alopecia-relevant animal models.

Independent Validation

• Pye K, et al. Activation of integrated stress response in human hair follicles by MPC inhibition. PLoS One. 2024. PMID: 38900734 — University of Manchester. Independent human follicle ex vivo study showing ISR activation alongside metabolic shift. Adds mechanistic complexity.

MPC Inhibitor Chemistry

• Huang Y, et al. Novel cyano-cinnamate MPC inhibitors. Bioorg Med Chem Lett. 2024. PMID: 39134097 — MPC inhibitor drug design advances.

Related (Same Research Group)

• Flores A, et al. LDH activity dispensable in squamous carcinoma cells of origin. Nature Comms. 2019. PMID: 30626875 — Safety-relevant: elevated LDH (which MPC inhibition promotes) was dispensable for SCC transformation in HFSCs.
• Flores A, Lowry WE. Mapping LDH activity in tissue. J Vis Exp. 2018. PMID: 29985359 — Methods paper.

Broader MPC Biology

• Petrelli F, et al. MPC regulates activation of quiescent adult neural stem cells. Science Advances. 2023. — MPC inhibition activates neural stem cells (cross-tissue validation of mechanism).
• McCommis KS, et al. MPC abundance mediates cardiac hypertrophy. Nature Metabolism. 2020. — MPC modulates cardiac metabolism.

Clinical Trials

• NCT06393452 — Phase 2a: Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA. Pelage Pharmaceuticals. Completed 2025.
• PP405-001 (Phase 1, not registered) — Results presented AAD 2024 Annual Meeting (late-breaking abstract).